ProShare Advisors
LENZ

ProShare Advisors’s LENZ Therapeutics LENZ Stock Holding History

ProShare Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,649
Closed -$60K – 2162
2022
Q1 		$60K Sell
1,649
-27
-2% -$1.69K ﹤0.01% 2102
2021
Q4 		$147K Buy
+1,676
New +$139K ﹤0.01% 2135

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

ProShare Advisors's LENZ Position: Q2 2022 in Review

ProShare Advisors sold out of LENZ Therapeutics (LENZ) in Q2 2022, closing a stake of 1,649 shares — an estimated $60K sold.

ProShare Advisors first reported a position in LENZ in Q4 2021 and held it in 2 quarters. The position peaked at $147K in Q4 2021. 63 funds tracked by Wall St. Rank hold LENZ as of Q2 2022.

  • ProShare Advisors reported no remaining LENZ Therapeutics position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 1,649 LENZ Therapeutics shares in Q2 2022, an estimated $60K.
  • ProShare Advisors first reported a position in LENZ Therapeutics in Q4 2021 and held it in 2 quarters.
  • ProShare Advisors's LENZ Therapeutics position peaked at $147K in Q4 2021.
  • 63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.